Frequency of HER-2/neu expression for tumour grade 1–2 and grade 3 lesions by joint ER/PR status
| Grade 1–2 | Grade 3 | |||||
|---|---|---|---|---|---|---|
| HER-2/neu* | Total | HER-2/neu* | Total | |||
| N | Positive | N | Positive | |||
| Data are numbers of patients (%). | ||||||
| *HER-2/neu was defined as negative when the DAKO score was 0, 1+, or 2+ and positive when 3+; †ER or PR was defined as negative when the H score was ⩽50, and positive when 51–300. | ||||||
| ER, oestrogen receptor; PR, progesterone receptor. | ||||||
| ER−PR−† | 20 (69.0%) | 9 (31.0%) | 29 | 148 (71.5%) | 59 (28.5%) | 207 |
| ER−PR+ | 9 (100.0%) | 0 (0.0%) | 9 | 7 (53.8%) | 6 (46.2%) | 13 |
| ER+PR− | 150 (92.6%) | 12 (7.4%) | 162 | 73 (81.1%) | 17 (18.9%) | 90 |
| ER+PR+ | 611 (97.3%) | 17 (2.7%) | 628 | 195 (87.1%) | 29 (12.9%) | 224 |
| Total | 790 (95.4%) | 38 (4.6%) | 828 | 423 (79.2%) | 111 (20.8%) | 534 |